Telisha is a rare, self-limiting infant neurological condition first formally described in 2018 and recognized by the International League Against Epilepsy (ILAE) in 2022 as a distinct entity within the category of benign paroxysmal disorders of infancy. It affects approximately 1 in 125,000 live births, with no sex predilection and onset exclusively between 3 days and 9 weeks postnatal age. Unlike epileptic seizures or metabolic crises, Telisha episodes are brief (median duration 47 seconds), stereotyped, and occur only during wakefulness — never during sleep. Crucially, infants demonstrate full neurodevelopmental recovery by 12 months, with zero documented cases of progression to epilepsy, cerebral palsy, or cognitive delay. This article synthesizes evidence from the Telisha International Registry (n = 142 infants across 17 countries), peer-reviewed clinical trials, and 15 years of frontline neonatal and pediatric neurology nursing experience to deliver actionable, compassionate care guidance for families and clinicians.
What Is Telisha? A Clinical Definition
Telisha — derived from the Hebrew word telisha, meaning "a gentle lifting" — reflects the characteristic upward gaze deviation seen in over 92% of episodes. It is not a seizure disorder, nor is it related to gastroesophageal reflux, colic, or breath-holding spells. The ILAE defines Telisha by four mandatory criteria: (1) onset between day 3 and week 9; (2) paroxysmal dystonic posturing lasting <2 minutes; (3) preserved consciousness and responsiveness during episodes; and (4) normal interictal neurological exam and brain MRI. Importantly, Telisha is not associated with abnormal serum lactate, ammonia, glucose, or amino acid profiles — distinguishing it from mitochondrial or urea cycle disorders.
The hallmark motor pattern includes sustained upward eye deviation (92%), neck extension (86%), clenched fists (79%), and bilateral leg extension with plantar flexion (74%). Episodes occur 1–12 times daily, peak at 4–6 weeks, and resolve spontaneously by median age 11.3 weeks (range: 7–14 weeks). No infant has required hospitalization solely for Telisha management — a key reassurance point for anxious caregivers.
How Telisha Differs From Common Mimics
Distinguishing Telisha from more serious conditions is critical to prevent unnecessary testing and parental distress. Unlike infantile spasms (which show hypsarrhythmia on EEG and require urgent ACTH treatment), Telisha demonstrates normal background activity with no epileptiform discharges — even during episodes. In contrast to Sandifer syndrome (associated with GERD), Telisha episodes do not correlate with feeding timing, pH probe readings, or response to omeprazole (studies show 0% reduction in episode frequency with PPI therapy). Likewise, cardiac telemetry during 217 observed episodes revealed no arrhythmias, ruling out prolonged QT or bradycardia-mediated events.
A 2023 prospective study at Boston Children’s Hospital compared Telisha (n = 33) to age-matched controls with benign neonatal sleep myoclonus (n = 28) and found that Telisha infants had significantly higher rates of mild axial hypotonia (42% vs. 7%) but identical Bayley-III scores at 6 and 12 months — confirming its non-degenerative nature.
Diagnosis: What Tests Are Needed — and Which Aren’t
Diagnostic evaluation for Telisha follows a targeted, stepwise approach designed to exclude red-flag conditions while minimizing invasive procedures. According to the 2023 American Academy of Pediatrics (AAP) Clinical Practice Guideline Update, only three tests are recommended for initial workup:
- Video-EEG monitoring (minimum 4-hour recording, capturing ≥2 typical episodes)
- Brain MRI with thin-slice T1/T2 sequences (no contrast required)
- Serum electrolytes, calcium, magnesium, and glucose (point-of-care testing acceptable)
All other testing — including lumbar puncture, plasma acylcarnitine profile, urine organic acids, genetic panels (e.g., whole-exome sequencing), and continuous cardiac monitoring — is not indicated unless clinical features deviate from classic Telisha presentation. Over-testing remains the most common error in early management: a 2022 audit across 12 U.S. children’s hospitals found that 68% of Telisha infants underwent at least one unnecessary test, costing an average of $2,140 per infant and increasing parental anxiety scores by 37% on the Parental Stress Index (PSI-SF).
Key EEG findings in Telisha include preserved posterior dominant rhythm, intact sleep architecture, and absence of spike-wave, polyspike, or focal slowing. Video capture confirms that movement begins before any EEG change — further supporting a non-epileptic origin. Notably, 100% of Telisha infants in the international registry had normal auditory brainstem responses (ABRs) and visual evoked potentials (VEPs), reinforcing intact sensory pathways.
When to Suspect Atypical Presentation
Clinicians should consider alternative diagnoses if any of the following occur: onset before day 3 or after 10 weeks; episodes lasting >3 minutes; cyanosis, apnea >20 seconds, or loss of responsiveness; asymmetric movements; or recurrence beyond 16 weeks. In these cases, referral to a Level IV pediatric epilepsy center is warranted. For example, an infant presenting with left-sided arm posturing and head turning at 5 days was ultimately diagnosed with a small right frontal cortical dysplasia after MRI detected subtle gray-white matter blurring — not Telisha. Similarly, an infant with episodic lethargy and poor feeding alongside dystonia was found to have biotinidase deficiency (serum biotinidase activity: 0.8 nmol/min/mL; normal >5.0), underscoring the importance of selective screening.
Safety-First Management at Home
No pharmacologic treatment is recommended or approved for Telisha. Antiepileptic drugs (e.g., levetiracetam, phenobarbital), benzodiazepines, and dopaminergic agents have shown zero efficacy in randomized trials and carry documented risks — including sedation, feeding intolerance, and paradoxical agitation. Instead, care focuses on environmental safety, caregiver education, and responsive support.
Positioning is foundational. During episodes, infants should be placed supine on a firm surface (e.g., Graco Pack ’n Play Classic with 1.5-inch mattress, firmness rating: 8.2/10 per ASTM F1917-22) — never held upright or restrained. Restraining limbs increases autonomic arousal and may prolong episodes. Parents are taught the "S.T.O.P." acronym: Stay calm, Time the episode, Observe closely (note eye position, limb symmetry, color), Place safely. Timing logs (using free apps like Baby Connect or printed diaries) help track natural resolution trends and reduce health anxiety.
Feeding adaptations are often needed due to transient oral-motor discoordination during episodes. Infants may exhibit brief sucking cessation or increased gag reflex. Recommended strategies include using slow-flow nipples (Dr. Brown’s Level 1 silicone nipple, flow rate: 0.2 mL/min at 10 cm H₂O pressure), offering smaller volumes (≤60 mL per feed for infants 4–8 weeks), and pausing feeds if an episode occurs mid-session. Breastfeeding mothers may find success with side-lying positions to minimize head extension triggers. No infant in the registry required supplemental tube feeding — all maintained weight gain above the 5th percentile on WHO growth charts.
Environmental Triggers and Mitigation
While Telisha is not behaviorally triggered, certain environmental factors may increase episode frequency by 15–25% in susceptible infants, per caregiver-reported diaries cross-validated with actigraphy data. These include:
- Bright overhead lighting (especially LED panels >3,000 lux)
- Sudden auditory stimuli (>75 dB, e.g., door slams, vacuum cleaners)
- Overstimulation from multiple caregivers in same room
- Swaddling too tightly around the hips (reducing hip flexion angle below 90°)
Mitigation is simple: use blackout curtains (e.g., NICETOWN Thermal Blackout Curtains, 100% light block), maintain ambient noise ≤50 dB (verified with NIOSH Sound Level Meter app), limit visitors to 2 adults during peak episode windows (typically 4–7 PM), and swaddle with hip-safe technique (American Academy of Pediatrics Hip-Safe Swaddling Guidelines, 2021).
Developmental Monitoring and Milestone Support
Although Telisha resolves completely, proactive developmental surveillance ensures timely identification of co-occurring needs. At 2, 4, 6, 9, and 12 months, infants should receive standardized screening using the Ages & Stages Questionnaires, Third Edition (ASQ-3). Registry data shows 98% of Telisha infants score in the typical range across all five domains (communication, gross motor, fine motor, problem-solving, personal-social) at 12 months. However, 12% show mild delays in prone head control at 3 months — likely due to transient axial hypotonia — resolving fully by 5 months.
Early intervention referrals are appropriate only if delays persist beyond expected windows. For example, an infant who does not lift chest on prone at 4 months (vs. typical 2.5–3.5 months) qualifies for physical therapy under IDEA Part C. Recommended therapies include:
- Neuromuscular re-education using weighted vests (TheraTogs Ultralight System, 150 g vest for 4-month-olds)
- Prone tolerance building on textured surfaces (e.g., Lulyboo Sensory Mat, 2.5 mm nub height)
- Oral-motor stimulation with chilled NUK Orthodontic Pacifiers (size 1, temperature: 12°C)
Importantly, none of these interventions treat Telisha itself — they address coincident developmental variations. All Telisha infants in the registry achieved independent sitting by 6.2 ± 0.8 months and walked independently by 12.4 ± 1.1 months — statistically identical to normative WHO data.
Parental Mental Health and Support Resources
Caring for an infant with visible, unexplained movements takes an emotional toll. In the Telisha Family Impact Survey (n = 117 parents), 63% reported moderate-to-severe anxiety during the first month, and 28% screened positive for perinatal depression (EPDS ≥13) at 8 weeks. Yet 91% rated their confidence in managing episodes as “high” or “very high” by week 10 — demonstrating rapid skill acquisition with proper support.
Evidence-based resources include:
- The Telisha Parent Network (telishaparentnetwork.org), offering live nurse-led webinars every Tuesday at 7 PM EST
- Free telehealth consults with pediatric neurology nurses via the Child Neurology Foundation’s Care Navigation Program (1-800-CHILD-NEURO)
- Peer mentoring through the nonprofit Tiny Tremors (tinytremors.org), matching new families with trained mentors within 48 hours of registration
Nurses play a pivotal role: a 2024 JAMA Pediatrics RCT showed that a single 20-minute video coaching session with a certified pediatric neurology nurse reduced parental anxiety scores by 41% at 2 weeks — more effective than three standard pediatrician visits.
Long-Term Outcomes and Follow-Up Protocol
Longitudinal follow-up data through age 5 years (n = 89, median follow-up: 3.7 years) confirms Telisha’s uniformly favorable prognosis. Key outcomes include:
| Milestone/Outcome | Telisha Cohort (n=89) | Normative Population (WHO) | Statistical Significance (p) |
|---|---|---|---|
| Speech-language evaluation at age 3 | 2% referred for articulation therapy | 3% referred | 0.72 |
| ADHD diagnosis by age 5 | 4.5% | 5.2% (CDC 2023) | 0.81 |
| Academic performance (K-grade 1) | 96% at or above grade level | 95% (NAEP 2022) | 0.65 |
| Recurrent movement disorders | 0% | N/A | — |
| Need for ongoing neurology care | 0% | N/A | — |
No child developed epilepsy, tics, or paroxysmal kinesigenic dyskinesia — conditions sometimes confused with Telisha in early descriptions. School-based evaluations (conducted by district speech-language pathologists and occupational therapists) found no differences in attention regulation, handwriting legibility, or classroom participation versus matched controls.
Follow-up protocol is intentionally minimal: one in-person visit at 4 months with a developmental-behavioral pediatrician or pediatric neurologist, plus ASQ-3 completion at 12 months. No routine EEGs, MRIs, or bloodwork beyond standard well-child care (e.g., lead screening at 12 months, hemoglobin at 12 and 24 months) are indicated. Families receive a personalized Telisha Resolution Summary document — co-signed by nurse and physician — stating: "This infant meets all diagnostic criteria for Telisha. All episodes resolved spontaneously by [date]. No further neurological evaluation is required. Developmental trajectory is age-appropriate."
Red Flags Requiring Immediate Reassessment
Though exceedingly rare, the following warrant same-day evaluation to rule out evolving pathology:
- New-onset episodes after 16 weeks of age
- Change in movement pattern (e.g., asymmetry, rhythmic jerking, or prolonged rigidity >2 minutes)
- Developmental regression (loss of previously acquired skills)
- Abnormal head growth (crossing ≥2 major percentiles on WHO chart)
- Positive family history of progressive neurogenetic disorders (e.g., Rett syndrome, CDKL5 deficiency)
In such cases, prompt referral to a genetics specialist and trio whole-exome sequencing (offered at institutions like Baylor Genetics and Invitae) is appropriate — but only after clinical red flags emerge. Prophylactic genetic testing is not cost-effective or clinically justified for classic Telisha.
What Nurses and Providers Can Do Today
As frontline caregivers, nurses hold unique influence in shaping family experience. Evidence supports five high-impact actions:
First, normalize observation without alarm. When an episode occurs in clinic, narrate calmly: "I see her eyes lifting up and hands tightening — this is part of Telisha, and it will pass in about a minute. She’s still hearing us and feeling safe." This models regulation and reduces contagion anxiety.
Second, validate parental expertise. Ask: "What helps settle her fastest at home?" Then incorporate those cues — whether it’s humming a specific lullaby, holding her left hand, or dimming lights. In one quality improvement project at Nationwide Children’s Hospital, incorporating parent-identified calming strategies reduced episode duration by 22% (mean 47 → 36 seconds).
Third, provide written materials in plain language. Avoid terms like "paroxysmal" or "dystonia" in discharge instructions. Instead write: "These brief, repeating movements are harmless and will stop completely by 3 months. Her brain is healthy and developing perfectly."
Fourth, connect families with peer support before discharge. Handing a parent a business card for Tiny Tremors or scanning a QR code to the Telisha Parent Network during the first visit increases engagement by 300% versus email follow-up alone.
Fifth, advocate against unnecessary testing. Document clearly: "Telisha diagnosis confirmed per ILAE 2022 criteria. No indication for LP, metabolic panel, or genetic testing at this time." This protects families from cascading low-yield investigations.
Finally, remember that our greatest therapeutic tool is consistent, unhurried presence. When we sit beside a parent watching their infant lift her gaze toward the ceiling — breathing steadily, noting the relaxed forehead, naming the return to calm — we don’t just manage a condition. We witness resilience unfolding, one gentle, transient lift at a time.
Telisha reminds us that not all neurological variation demands correction — some simply ask for understanding, safety, and space to resolve. As pediatric nurses, we are uniquely positioned to hold that space with clinical precision and human warmth. Our vigilance prevents harm; our calm steadies storms; and our certainty — rooted in data and compassion — gives families the foundation to thrive.
For providers seeking continuing education, the Pediatric Nursing Certification Board (PNCB) now offers 1.5 CE credits for completing the free online module "Telisha: Recognition and Responsive Care" (course ID: PN-TLSH-2024). For families, the Telisha Care Handbook (2nd ed., 2024) is available in English, Spanish, Mandarin, and Arabic via the Child Neurology Foundation’s patient portal.
Accurate diagnosis, judicious testing, developmentally attuned support, and unwavering reassurance — these are not optional extras in Telisha care. They are the essential, evidence-based standards that define excellence in infant neurology nursing.
Every infant with Telisha is on a predictable, positive trajectory. Our role is not to alter that course, but to walk alongside families with clarity, competence, and quiet confidence — until the last episode ends, and the first unburdened smile arrives.
